3 unchanged sentences
In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.
−Removed: The following table summarizes the activity, by month, during the three months ended September 30, 2023:
+Added: The following table summarizes the activity, by month, during the three months ended March 31, 2024:
Period Total Number of
1 unchanged sentence
Purchased, which were also Part of the Publicly Announced Plans or Programs
−Removed: Maximum Number
−Removed: (or Approximate
−Removed: Dollar Value) of
−Removed: Shares that May Yet Be
−Removed: Purchased Under
−Removed: July 29,132 $ 1.56 $ 3,348,711
−Removed: August 53,518 1.68 3,258,885
−Removed: September 33,914 1.94 3,192,982
+Added: Maximum Number (or
+Added: Approximate Dollar
+Added: Value) of Shares (or
+Added: Units) that May Yet Be
+Added: Purchased Under the
+Added: Plans or Programs
+Added: Maximum number (or Approximate Dollar Value) of Shares (or Units) that May be Purchased Under the Publicly Announced Plan
+Added: January 22,874 $2.08 $ 47,546 $ 2,957,839
+Added: February 22,630 $2.16 $ 48,775 $ 2,909,064
+Added: March 80,366 (1) $1.56 $ 150,278 $ 2,758,786
Total 125,870
−Removed: 10.1 Revolving Credit Loan Agreement, dated as of September 5, 2023, by and between Cumberland Pharmaceuticals Inc.
−Removed: and Pinnacle Bank, incorporated herein by reference to Exhibit 10.1 of the Company’s Form 8-K (File No.:
−Removed: 001-33637) as filed with the SEC on September 6, 2023.
−Removed: 31.1* Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: 31.2* Certification of Chief Financial Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
−Removed: 32.1** Certification of Chief Executive and Principal Financial Officer Pursuant to 18 U.S.C.
−Removed: Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: 101.INS* INLINE XBRL INSTANCE DOCUMENT - THE INSTANCE DOCUMENT DOES NOT APPEAR IN THE INTERACTIVE DATA FILE BECAUSE ITS XBRL TAGS ARE EMBEDDED WITHIN THE INLINE XBRL DOCUMENT.
−Removed: 101.SCH* INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
−Removed: 101.CAL* INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
−Removed: 101.DEF* INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
−Removed: 101.LAB* INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
−Removed: 101.PRE* INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
−Removed: 104 COVER PAGE INTERACTIVE DATA FILE (FORMATTED AS INLINE XBRL AND CONTAINED IN EXHIBIT 101)
−Removed: * Filed herewith.
−Removed: ** Furnished herewith.
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
−Removed: Cumberland Pharmaceuticals Inc.
−Removed: November 13, 2023 By:
−Removed: /s/ John Hamm
−Removed: Chief Financial Officer and Duly Authorized Officer
+Added: (1) Of this amount, 51,607 shares were repurchased directly in private purchases at the then-current fair market value of common stock.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.